What You Should Know:
– Mammoth Biosciences, the company bringing CRISPR out of the lab to help fight COVID-19 announced a partnership with lab giant Agilent to automate and scale its CRISPR-based high throughput testing system.
– Building on existing partnerships with Hamilton and Merck, this deal will help deliver a workflow capable of performing more than 4,000 COVID-19 tests per day.
Mammoth Biosciences, Inc. today announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent’s Bravo automation workstation and Mammoth Biosciences’ DETECTR BOOSTTM assay. The partnership marks Agilent’s commitment to be a prominent supplier of solutions for the COVID-19 and infectious disease diagnostics market.
This project is supported by the NIH Rapid Acceleration of Diagnostics (RADx) program and has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00011.
Partnership Addresses Need for More Widespread COVID-19 Testing Options
Together, the DETECTR BOOSTTM SARS-CoV-2 Kit and Agilent automated liquid handling system would provide a complete workflow for high-throughput COVID-19 testing – a turnkey, sample-to-answer solution for commercial laboratories that enables a multi-fold increase in testing capacity compared to most currently available solutions, while ensuring highly accurate and sensitive results required for SARS-CoV-2 diagnostic testing. The assay and automation solution will leverage Agilent’s Bravo Liquid Handling System, including the Bravo BenchCel DB Workstation and BioTek plate readers, predicted to deliver a workflow capable of performing over 4,000 COVID-19 tests per day.
“A highly-automated workstation for SARS-CoV-2 testing provides the capacity needed to bring routine, robust testing to the broader market,” said David Edwards, associate vice president for marketing in the Agilent mass spectrometry division. “By partnering with Mammoth Biosciences, we will be able to provide a simplified workflow that addresses the specific needs of high-throughput clinical testing laboratories. Agilent is honored to contribute in the fight to curtail the impact of COVID-19 alongside the global scientific community.”
